Week of August 17th, 2020 | Vol. 9, Issue 33
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events

Quick Links

Contact Information
Managing Director
Business Development

Managing Director
Head of M&A and Capital Advisory

Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.

For more information about our consumer healthcare JV with The Emerson Group, Daybreak Consumer Care, click here.
Recent Materials Providing Insight Into Healthcare Related Industries
Current M&A Pipeline
Representative Current Retained Sell-Side And Partnering Opportunities
Project Aspen
Sell-side | Pharma Services | Multi-national contract manufacturing and packaging organization

Project Athena
Sell-side | Medical Device | Novel medical device for the treatment of pelvic organ prolapse

Project Vista
Out-partnering | Pharma | Seeking commercial partner for novel, liquid-format riluzole treatment of ALS

Project Seal
Buy-side | Pharma | Seeking Pain and CNS products as well as legacy/tail commercial pharma assets

Project Olympus
Sell-side | Pharma | Portfolio of generic injectable products
Eisai Inc., an oncology- and neurology-focused pharmaceutical company and the U.S. subsidiary of Eisai Co., Ltd., based in Tokyo, Japan, has unveiled plans to relocate its New Jersey-based headquarters to the technologically-advanced and cutting-edge ON3 property in Nutley, NJ. The company plans to transfer up to 1,200 Eisai corporate staff and research and development functions from Woodcliff Lake to Nutley in late 2021.

An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
Pharma & Biotech
17 transactions totaling $1,792 million
Supplies, Equipment & Services
14 transactions totaling $4 million
Healthcare IT & Managed Care
6 transactions totaling $391 million
Healthcare Facilities & Distributors
9 transactions totaling $121 million
Pharma & Biotech
26 transactions totaling $1,207 million
Supplies, Equipment & Services
17 transactions totaling $659 million
Healthcare IT & Managed Care
18 transactions totaling $314 million
Healthcare Facilities & Distributors
2 transactions totaling $31 million
Pharma & Biotech
37 transactions totaling $4,532 million
Supplies, Equipment & Services
11 transactions totaling $4,577 million
Healthcare IT & Managed Care
3 transactions totaling $436 million
Healthcare Facilities & Distributors
0 transactions
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
August 13, 2020 - Fierce Biotech
While many companies have faltered under the spread of COVID-19, others may be doing a little too well for some tastes—with Qiagen’s investors turning down Thermo Fisher’s multibillion-dollar takeover proposal, following rocketing demand for its testing products.

August 12, 2020 - Contract Pharma
The U.S. government has secured 100 million doses of mRNA-1273 from Moderna, a biotech pioneering messenger RNA (mRNA) therapeutics and vaccines, as part of its goal of securing early access to safe and effective COVID-19 vaccines for the American people.

August 11, 2020 - Fierce Biotech
After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs to help lead its new acquisition’s R&D.

August 11, 2020 - Fierce Biotech
Bayer has struck a $425 million upfront deal to buy KaNDy Therapeutics in the belief its treatment for menopause-related hot flashes has blockbuster potential. KaNDy recently completed a phase 2b trial of neurokinin-1,3 receptor antagonist NT-814, teeing it up to start a pivotal study next year.
Welcome to Bourne, let's talk.

Since our founding in 2001, Bourne Partners has remained focused on fulfilling the unique needs of established, middle-market healthcare and pharmaceutical companies across the globe. Our track record includes advising middle market companies in healthcare M&A assignments totaling more than $7 billion, and growing companies into successful and well-positioned pharmaceutical enterprises.